

Recent Advances in the Pharmacological Management of Pain

Josée Guindon,¹ Jean-Sébastien Walczak¹ and Pierre Beaulieu^{1,2}

1 Department of Pharmacology, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada

2 Department of Anesthesiology, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada

Abstract

Pain is an unpleasant sensation that originates from ongoing or impending tissue damage. Management of different types of pain (acute, postoperative, inflammatory, neuropathic or cancer) is the most frequent issue encountered by clinicians and pharmacological therapy is the first line of approach for the treatment of pain. This review presents and discusses recent clinical advances regarding both the improvements in delivery of analgesic drugs and improvements in the design of analgesic molecules. The new modalities of administration of analgesics used in the clinic are reviewed, including skin patches, oral and mucosal sprays, transdermal delivery systems and intranasal administration. New insights are then presented on standard drugs used to relieve pain, such as opioids (including tramadol), NSAIDs including selective cyclo-oxygenase-2 inhibitors, paracetamol (acetaminophen), local anaesthetics and adjuvant analgesics such as antidepressants, anticonvulsants (gabapentin and pregabalin), cannabinoids, ketamine and others (e.g. nefopam). Although the understanding of pain mechanisms has improved significantly recently, much more is yet to be discovered and awaited. Broadening of our knowledge is needed to improve basic and clinical research in this field in order to better alleviate pain in millions of people.

Pain is an unpleasant sensation, ranging in intensity from slight through severe to indescribable. The word 'pain' comes from the Latin word *peona* meaning punishment or penalty. The two most common forms of pain reported in the US are headaches, affecting 45 million people, and back pain, involving 6 million each year. Cancer-related pain affects 9 million people each year. Management of pain for the treatment of moderate, chronic or severe pain in inflammatory, neuropathic, postoperative and cancer conditions is the burden of clinicians dealing with these patients; trying to improve their quality of life and to diminish their pain states.

Different pharmacological approaches exist for the treatment of pain such as the use of paracetamol (acetaminophen), NSAIDs, opioids, anticonvul-

sants, antidepressants, local anaesthetics, cannabinoids, ketamine and others (table I). Furthermore, along with standard methods of administration, novel modalities have become available in the last few years, including transdermal patches, oral sprays, intranasal instillation and many others. Despite the discovery of multiple mechanisms involved and a better understanding of the pain pathways, our handling of pain in patients is still inadequate and thus needs rethinking. In particular, the prescription of drugs for the management of pain is not adequate and should take into consideration multiple factors (table II) to optimise the efficacy of the treatment.

This review focuses on the new pharmacological approaches in the treatment and management of pain, notwithstanding the type of pain involved.

Table I. Drugs commonly used in the treatment of pain: classical analgesics and new adjuvants

Opioids: alfentanil, buprenorphine, butorphanol, fentanyl, hydromorphone, pethidine (meperidine), methadone, morphine, nalbuphine, oxycodone, remifentanyl, sufentanyl, tramadol
NSAIDs: diclofenac, ibuprofen, ketoprofen, ketorolac, naproxen
Coxibs^a: celecoxib, etoricoxib, lumiracoxib, parecoxib
Antidepressants: bupropion, duloxetine, imipramine, venlafaxine
Antiepileptic drugs: gabapentin, lamotrigine, pregabalin
Cannabinoids: ajulemic acid, cannabis, Δ^9 -tetrahydrocannabinol/cannabidiol, dronabinol, nabilone
Local anaesthetics: bupivacaine, levobupivacaine, lidocaine 5%, ropivacaine
Others: clonidine, ketamine, nefopam, neostigmine, paracetamol (acetaminophen)
a Selective cyclo-oxygenase type 2 inhibitors.

1. New Modalities of Drug Administration

Although patients may be able to control their pain by self-administration of intravenous opioids using patient-controlled analgesia (PCA) devices, which provide better pain control and greater patient satisfaction compared with conventional parenteral analgesic regimens,^[1] over the years new approaches have been developed (figure 1).

Firstly, transdermal administration of fentanyl and buprenorphine was reported some years ago.^[2,3] This concept of transdermal application of lipophilic opioids in the form of patches has been evolving for several years. Its initial use was proposed for chronic pain and more specifically for cancer pain.^[4-6] Currently, it is widely used in different pain conditions,^[7,8] but not in acute postoperative pain conditions because the therapeutic concentrations are obtained between 12 and 32 hours after the patch is applied^[9,10] for drugs such as fentanyl. As an accumulation of fentanyl can be observed with the patches, the administration of low doses of fentanyl hydrochloride by iontophoresis was developed.^[11-13] This technique uses a low intensity electrical current that allows fentanyl to diffuse from a reservoir to the skin to rapidly obtain an effective site concentration, as explained by the favourable pharmacokinetic properties of fentanyl. This patient-controlled transdermal system is a compact self-contained system that is easily applied to the upper outer arm or chest and provides postoperative pain control equivalent

to intravenous morphine PCA.^[12,13] Furthermore, there is no subcutaneous accumulation of fentanyl with this approach, and therefore no risk of residual analgesia is observed following its withdrawal.^[14]

Another approach is the administration of opioids by intranasal spray. This technique has been investigated for fentanyl, alfentanil, sufentanyl, pethidine (meperidine), diamorphine and butorphanol tartrate. It can provide analgesia in different pain conditions and can be as effective as intravenous administration.^[15-20] This new method of opioid delivery provides good bioavailability, since it avoids hepatic first-pass metabolism because it is absorbed directly by the mucous nasal membrane. Other advantages of this technique are its effectiveness, its noninvasive method of administration and ease of use.^[21]

The delivery of opioids by sublingual spray has only been developed for oxycodone hydrochloride and was demonstrated to provide fast pain relief in an acute animal model;^[22] therefore, further investigations are needed to assess its effectiveness in humans. Furthermore, although the research on cannabis for pain treatment is relatively new compared with that already carried out with opioids, there have been a few studies testing the sublingual spray delivery of Δ^9 -tetrahydrocannabinol (THC) combined with cannabidiol (CBD) mixed in a 1 : 1 ratio (Sativex[®] 1). It has been demonstrated that cannabinoids given in this form produced analgesia in chronic, neuropathic pain conditions and multiple sclerosis.^[23-26] This new formulation is in phase III clinical trials for multiple sclerosis patients in the

Table II. Multiple factors influencing drug treatment of pain

Cultural belief
Personal experience
Medical history
Pain intensity
Reduced work status
Interference with meaningful activity
Other diseases interacting
Drug-drug interactions
Toxicity
Cost
Patient acceptance and compliance
Patient expectations and beliefs about the cause of pain

1 The use of trade names is for product identification purposes only and does not imply endorsement.




Fig. 1. Overview of recent developments in routes of administration and associated drugs used to treat pain. **PCA** = patient-controlled analgesia; Δ^9 -THC/CBD = Δ^9 -tetrahydrocannabinol/cannabidiol.

UK and has been granted approval in Canada for the symptomatic relief of neuropathic pain in multiple sclerosis.^[27,28]

Another method of drug administration is the use of oral transmucosal analgesia. Fentanyl citrate (Actiq®) is a new opioid formulation that incorporates fentanyl into a lozenge and allows drug delivery through the buccal mucosa as a unique delivery system. This kind of absorption avoids first-pass metabolism, yielding a bioavailability substantially greater than with oral administration. It is used for the treatment of breakthrough pain in cancer patients already stabilised with their pain medications.^[29-31]

Morphine can be rapidly and extensively absorbed from the respiratory tract, leading to a favourable pharmacokinetic profile for fast pain relief;^[32] therefore, the development of the AERx® pain management system consists of an advanced pulmonary delivery system designed to efficiently deliver bolus aerosols of drugs, such as morphine or fentanyl, to the periphery of the lungs, leading to rapid absorption into the systemic circulation.^[33,34] Inhaled mor-

phine or fentanyl delivered from this AERx® system produces an analgesic effect in acute pain and breakthrough cancer pain.^[35-37] Moreover, the encapsulation of fentanyl in liposomes has the potential to control the uptake of fentanyl by the lungs and thus provide sustained drug release.^[38]

Another system of administration is the use of biodegradable microspheres, which have a special importance since it is possible to target drugs and to provide controlled release. It was demonstrated that microspheres loaded with diclofenac, rofecoxib or nalbuphine can prolong drug release,^[39-41] which can be particularly useful in treating joint pain, such as in osteoarthritis. For instance, a 10-fold increase in the concentration of rofecoxib in the joints of rats was observed 24 hours after its intra-articular injection when it was encapsulated in microspheres compared with the drug in a standard solution.^[41]

2. NSAIDs

Traditional NSAIDs are widely prescribed as analgesics and anti-inflammatory agents because of

their inhibition of prostanoid synthesis through blockade of both cyclo-oxygenases (COX-1 and COX-2). Thus, selective COX-2 inhibitors, named 'coxibs', were developed with the aim of reducing the incidence of serious gastrointestinal adverse effects associated with traditional NSAIDs in long-term anti-inflammatory analgesic therapy.^[42] The first coxibs approved for the relief of osteoarthritis, rheumatoid arthritis, acute pain associated with dental surgery and primary dysmenorrhoea were rofecoxib and celecoxib.^[43] Novel coxibs with improved biochemical selectivity were also developed – such as etoricoxib,^[44,45] valdecoxib,^[46] parecoxib (the prodrug of valdecoxib)^[47-49] and lumiracoxib^[50-53] – for their use in the treatment of osteoarthritis, rheumatoid arthritis, acute pain and post-operative pain in noncardiac surgical patients. However, major concerns regarding the safety profile of these drugs has resulted in considerable debate and subsequent withdrawal of two of them: rofecoxib for cardiovascular issues^[48,54,55] and valdecoxib for serious cutaneous adverse reactions.^[48,56,57] Nonetheless, coxibs, such as parecoxib and valdecoxib, are useful adjuncts to opioids, corresponding to a multimodal analgesia for the treatment of postoperative pain in noncardiac surgical patients.^[49] In the meantime, the use of these drugs remains under scrutiny, particularly in cardiovascular at-risk populations. Their use should be restricted to individuals who do not respond to traditional NSAIDs or who have an increased risk of gastrointestinal complications, and for patients with low cardiovascular risk.^[42]

Although it is widely accepted that NSAIDs are less potent than opioids for the treatment of pain, several NSAIDs provide a documented 30–50% morphine-sparing effect and improve analgesia when co-administered with PCA morphine. Furthermore, Marret and colleagues^[58] showed in a meta-analysis that NSAIDs decreased postoperative nausea and vomiting by 30% and sedation by 29%, but had no significant effects on pruritus, urinary retention and respiratory depression. Finally, it was demonstrated that pre-emptive NSAIDs were of no analgesic benefit when compared with post-incisional administration of these drugs.^[59] Clinical studies have confirmed that coxibs can produce analgesia

similar to NSAIDs for moderate to severe acute pain.^[60]

However, there are well recognised gastrointestinal, cardiac, renal and other adverse effects associated with the use of these drugs. Large outcome and epidemiological studies, and postmarketing surveillance data suggest that while coxibs do confer improved gastrointestinal safety, they are not devoid of gastrointestinal effects during long-term use.^[52] The cardiovascular effects (leading to myocardial infarction and stroke) of coxibs have emerged as a major concern in recent years.^[45,61] Indeed, due to their reversible inhibition of COX activity, NSAIDs can inhibit platelet aggregation. However, this may not be the case with new coxibs. COX-2 inhibition alone may increase the risk of vascular thrombus formation by upsetting the balance of pro- and anti-platelet aggregation effects: thromboxane (TX)A₂ synthesis is primarily a COX-1-induced effect and prostaglandin (PG)I₂ synthesis a COX-2 effect. These thrombotic properties have been reported after various long-term use of coxibs (rofecoxib and celecoxib) and also with valdecoxib and parecoxib in acute pain management following cardiac revascularisation surgery.^[62]

In susceptible patients, NSAIDs cause acute renal failure due to the inhibition of the biosynthesis of prostaglandins involved in the maintenance of renal blood flow. Both isoforms of COX are expressed in the kidney, therefore coxibs can cause sodium retention and decrease glomerular filtration rate to a similar extent as nonselective NSAIDs in patients at risk for adverse renal effects.^[63]

Therefore, NSAIDs should be part of a multimodal analgesia approach (see section 11) and should be prescribed when possible. The risks associated with traditional NSAIDs are well known and should be anticipated. The long-term use of coxibs is associated with thrombotic events that need further investigation.^[61]

Finally, the use of topical NSAIDs has been investigated recently to reduce pain associated with osteoarthritis. The application of topical diclofenac solution on the knee is able to produce significant pain relief in patients.^[64-66] This topical diclofenac solution can provide efficacious, well tolerated and site-specific treatment for osteoarthritic pain, with

minimal systemic adverse effects and only minor local skin irritation.

3. Paracetamol (Acetaminophen)

Paracetamol is commonly used for postoperative or cancer pain in combination with more potent analgesics.^[67-70] It is well established as an effective and very well tolerated agent in the management of mild to moderate pain. As paracetamol has none of the renal or cardiovascular adverse effects that characterise anti-inflammatory drugs, it can be used in both NSAID- and opioid-sparing roles. A systematic review by Romsing et al.^[71] examined the effects of rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs for postoperative analgesia. Evidence was found of a clinically relevant analgesic effect of rectal and parenteral paracetamol. Furthermore, the concurrent use of paracetamol and an NSAID was superior to paracetamol alone, although no evidence was found of superior analgesic effect of the combination compared with the NSAID alone. Another review of postoperative pain studies comparing paracetamol (minimum 1g) with NSAIDs showed that paracetamol has analgesic efficacy comparable to that of NSAIDs in many of the studies reviewed, but overall, NSAIDs seem to be superior for postoperative pain management, although there seem to be differences in the efficacies of paracetamol and NSAIDs depending on the type of surgery performed.^[72] Finally, paracetamol combined with PCA morphine induced a significant morphine-sparing effect, but did not change the incidence of morphine-related adverse effects in the postoperative period.^[73]

Recently, an intravenous formulation of paracetamol has been introduced and its pharmacokinetic properties have been characterised,^[74] providing multimodal analgesia (see section 11) for pain management when they are combined with opioids.^[75] This multimodal approach decreases the amount of opioids needed and reduces their adverse effects, while improving the quality of cancer or postoperative analgesia.^[76] The intravenous formulation of a prodrug of paracetamol, propacetamol, was administered to adults as an alternative to ketorolac in the perioperative period. Propacetamol reduced PCA morphine consumption by 22–46% in patients undergoing major orthopaedic surgery.^[73] A new

intravenous formulation of paracetamol, *Perfalgan*TM, which is equivalent to propacetamol but with better injection-site tolerance, has recently been developed.^[59]

Finally, despite widespread use of paracetamol in medical everyday life, the mechanism of its analgesic action still remains poorly understood.^[77] However, there is now human evidence suggesting that the mechanism of its analgesic action involves the serotonergic system.^[78]

Therefore, the very low cost and apparent risks of paracetamol therapy (following maximum dosage recommendations) suggest a highly favourable risk/benefit ratio that might justify a role for paracetamol as a near-routine background analgesic.

4. Nefopam

Nefopam is a potent central non-opioid analgesic used clinically to improve postoperative opioid analgesia in patients by significantly reducing the amount of morphine needed, by 20–50%.^[79-82] Interestingly, it has been shown that the early administration of nefopam during the perioperative phase significantly improves postoperative analgesia.^[79,80] Furthermore, an analgesic synergistic effect between nefopam and ketoprofen has been described.^[83] Moreover, this compound does not have any effects on respiratory and haemostasis functions, but is devoid of antipyretic properties.^[84-86] It is centrally acting at the supraspinal and spinal levels,^[87,88] and has been identified as a monoamine uptake inhibitor.^[89-91] The antinociceptive effect of nefopam could be explained by its activation of serotonergic descending inhibitory pathways^[92] and its antihyperalgesic activity by the modulation of glutamatergic transmission.^[93,94]

5. Recent Advances with Opioids

Tramadol, although not a new opioid but recently rediscovered, is a weak opioid agonist that has been shown to be effective in the treatment of neuropathic pain,^[95] producing equivalent analgesia when compared with pethidine in postoperative pain conditions.^[96] Indeed, tramadol is an alternative option for postoperative pain relief after tonsillectomy in children, as it is associated with less nausea than morphine.^[97] Tramadol alone or in combination with

paracetamol produces a comparable relief in low back pain patients,^[98] and the combination of tramadol and paracetamol is as effective as the combination of hydrocodone and paracetamol in relieving acute musculoskeletal pain.^[99] Tramadol can be administered orally or intravenously, and is an interesting alternative to other opioids for pain management.

The role of methadone has been stigmatised by its longstanding use in maintenance programmes for opioid addiction. However, methadone is being increasingly recognised as a valuable second-line opioid analgesic for chronic noncancer pain, especially neuropathic pain.^[100-102] It is also used in the treatment of cancer pain.^[103-105] Methadone has undergone a renaissance because it has high oral bioavailability, a long duration of action, a lack of active metabolites, antagonist properties at *N*-methyl-D-aspartate receptors and blocks the reuptake of monoamines,^[106] making it useful in the treatment of neuropathic and cancer pain.

Remifentanyl, an opioid agonist characterised by a rapid onset and a short duration of action, is an analogue of fentanyl and can be used to decrease postoperative pain after surgical procedures.^[107,108] This short-acting opioid is administered intravenously and is commonly used to provide adequate analgesia following cardiac surgery.^[109,110] Remifentanyl can also be used in a PCA mode in patients in labour when regional techniques are not possible.^[111,112] Indeed, the satisfaction of the analgesia with remifentanyl given as a PCA was higher than the values obtained with pethidine analgesia for women in labour.^[113]

Opioid-related constipation is one of the most frequent adverse effects of chronic pain treatment. Enteral administration of naloxone or naltrexone blocks opioid action at the intestinal receptor level, but has low systemic bioavailability as a result of marked hepatic first-pass metabolism.^[114] Methylnaltrexone is a peripheral opioid receptor antagonist undergoing phase III clinical trials for the treatment of opioid-induced constipation in patients with advanced medical illness who are being treated with opioids for pain. It does not cross the blood-brain barrier in humans and reverses the opioid effects without interfering with pain relief.^[115] Some

opioid-induced adverse events that this kind of drug may potentially target include constipation, nausea/vomiting, cough suppression and urinary retention.

6. Ketamine

Ketamine is an analogue of phencyclidine with a mechanism of action that is associated with antagonism of *N*-methyl-D-aspartate receptors. This dissociative anaesthetic has a role to play in the treatment of pathological pain conditions such as neuropathic pain.^[116] Indeed, the administration of low-dose ketamine either intravenously or subcutaneously decreases pain in nonresponsive neuropathic pain patients from the start of the infusion treatment to the end.^[117] A cream made of 1% ketamine combined with 2% amitriptyline also demonstrated analgesic effectiveness in the treatment of peripheral neuropathic pain.^[118] Meanwhile, ketamine has also been used successfully for the treatment of intractable cancer pain.^[119,120]

For perioperative pain management, preoperative epidural administration of a low dose of ketamine combined with midazolam has been found more effective in relieving postoperative pain than the use of ketamine alone.^[121] Furthermore, a qualitative systematic review of the role of *N*-methyl-D-aspartate receptor antagonists in preventive analgesia reported nine positive and seven negative studies about intravenous ketamine administration.^[122] Furthermore, a recent meta-analysis reported that when administered intravenously during anaesthesia in adults, ketamine decreased postoperative pain intensity for up to 48 hours, decreased cumulative 24-hour morphine consumption and delayed the time to first request of rescue analgesic. However, when assessing the clinical relevance of these potentially beneficial effects, several issues needed to be considered and the authors concluded that despite many published randomised trials, the role of ketamine, as a component of perioperative analgesia, remains unclear.^[123]

In conclusion, the place of ketamine in the treatment of various pain conditions and its effects in long-term medicinal use still need further investigation.

7. Antidepressants

The standard and first-line treatment for different kinds of neuropathic pain is generally antidepressant drugs, and more specifically, tricyclic antidepressants, where the main effect is to non-selectively inhibit the uptake of noradrenaline (norepinephrine) and serotonin.^[124-126] There is also new evidence suggesting that some tricyclic antidepressants can block sodium channels, which may contribute to their antihyperalgesic efficacy.^[127] Although the effectiveness of amitriptyline in relieving neuropathic pain has been shown in different studies,^[128-130] its adverse effects (sedation, confusion, blurred vision, postural hypotension and many others) are the main constraint to its use and reason for withdrawal of patients who experience those adverse effects.^[124] Therefore, new drugs have been developed to address the problem of these adverse effects.

Venlafaxine, which is a serotonin and noradrenergic reuptake inhibitor, has been the most investigated, and it is devoid of action on muscarinic-cholinergic, histaminic and α_1 -adrenergic receptors responsible for the common adverse effects seen with tricyclic antidepressants.^[124,131] Venlafaxine is efficacious in the treatment of neuropathic pain^[131] and considered as effective as imipramine (tricyclic antidepressant) in the treatment of pain related to polyneuropathy.^[132] Newer antidepressants, such as selective noradrenaline and serotonin reuptake inhibitors (e.g. duloxetine), have demonstrated obvious benefits, a reduction in toxicity and are effective in the treatment of diabetic neuropathic pain.^[133-135] Other studies have also demonstrated that bupropion, a noradrenaline and dopamine uptake inhibitor, is highly efficacious in relieving peripheral neuropathic pain.^[136,137]

In summary, antidepressants represent useful pharmacological tools for clinicians in the treatment of neuropathic pain.

8. Antiepileptic Drugs

Carbamazepine and phenytoin were the first antiepileptic drugs (AEDs) to be used in controlled clinical trials to relieve painful diabetic neuropathy and paroxysmal attacks in trigeminal neuralgia.^[138] However, since they have significant adverse effects, newer AEDs have been developed.^[139]

Gabapentin and pregabalin (gabapentin analogue) act at the $\alpha_2\delta$ subunit of the voltage-gated calcium channels to reduce neurotransmitter release.^[140,141] Laboratory evidence suggests that they can both inhibit hyperalgesia and allodynia evoked by a variety of neural insults, including peripheral trauma, diabetes mellitus and chemotherapy.^[142] Clinical evidence in most studies supports their analgesic efficacy in diabetic neuropathy and postherpetic neuralgia.^[133,140,142] Gabapentin has also been shown to reduce chronic neuropathic pain more effectively when combined with morphine, and both were able to be given at lower doses than each drug alone.^[126] Lamotrigine is another new AED that blocks voltage-dependent sodium channels and inhibits glutamate release;^[143] it is effective in trigeminal neuralgia, painful peripheral neuropathy and for post-stroke pain.^[127,138]

Future research efforts are necessary to fully understand the mechanism of action of AEDs, and to clearly characterise their safety and efficacy in the treatment of chronic pain conditions. For acute pain management, results from recent clinical trials demonstrate analgesic efficacy, an opioid-sparing effect, and possible postoperative functional improvement associated with gabapentin.^[144] Other trials also suggest the potential analgesic efficacy of other AEDs including pregabalin, lamotrigine and possibly oxcarbazepine.^[144] This was also confirmed in a recent meta-analysis showing that gabapentin given preoperatively decreased pain scores and analgesic consumption in the first 24 hours after surgery. However, the clinical significance of this finding has yet to be determined. Furthermore, a significant reduction in the incidence of adverse effects could not be demonstrated.^[145]

9. Local Anaesthetics

Continuous nerve blockade is the only available medium- to long-term modality that blocks evoked pain. Decreased nausea and vomiting, and increased patient satisfaction are consequences of continuous peripheral nerve blocks, whereas other interesting concepts, such as improved rehabilitation and decreased incidence of postsurgery chronic pain syndromes, are currently receiving attention.^[146] The use of continuous peripheral nerve blocks at home has also been recently reviewed.^[147]

The 5% lidocaine patch has been demonstrated to relieve localised pain in postherpetic neuralgia, with no increase in adverse effects.^[148] For countries where this patch formulation is not available (e.g. Canada), pharmacists can make up a gel or a cream at a concentration between 5% and 10%.^[139,149]

Combinations of local anaesthetics with other adjuvants, such as morphine, clonidine, ketorolac or ketamine, have been reported. Intra-articular morphine (0.5–1mg) with bupivacaine provided long-lasting analgesia after knee arthroscopy,^[60] and the bupivacaine/ketamine combination was superior to intra-articular ketamine analgesia following arthroscopic knee surgery.^[150]

Finally, wound or intra-articular infiltration with local anaesthetics with or without the use of continuous infusions via subcutaneous catheters is being reassessed.^[151,152] For example, Karamanlioglu et al.^[152] compared efficacy and patient outcome of wound infiltration with ropivacaine, lornoxicam or their combination, for control of pain following thyroid surgery. These authors showed that wound infiltration with a combination of ropivacaine 0.75% plus lornoxicam 8mg improved postoperative pain control and patient comfort, and decreased the need for opioids compared with the use of either drug alone. In another study, Harvey et al.^[151] evaluated the efficacy of a subacromial PCA infusion of ropivacaine 0.2% versus saline for postoperative pain control following arthroscopic shoulder surgery. They showed that the use of subacromial ropivacaine infusion provided effective postoperative pain control.

10. Cannabinoids

The use of cannabinoids for the treatment of acute and chronic pain has a long and well documented history.^[153] For chronic pain, the evidence is mounting that cannabinoids may constitute a new class of agents to add to the pharmaceutical toolbox in the management of chronic pain.^[23-26,154-159] The effects of cannabinoids on pain (including peripheral and central neuropathic pain states, and spasticity) are measurable and meaningful to patients, and suggest that with appropriate prescribing and monitoring some additional benefit to some patients may be expected with cannabinoid therapy. Short-term adverse effects are well described and are often the

main drawbacks to patient compliance with therapy. More specific information is required on the long-term adverse effects of cannabinoid therapy, including drug-drug interactions, tolerance, cognitive impairment and risks of addiction. However, these issues are not unique to cannabinoids and indeed point to the need for pain physicians to exercise diligence in following patients on psychoactive medications.^[27]

The role of cannabinoids in postoperative pain management has been recently evaluated. The conclusions from only four studies show that cannabinoids are not ideally suited to manage postoperative pain, being moderately effective,^[160,161] no different from placebo^[162] or even antianalgesic at high doses.^[163]

11. Multimodal Approach

A main concern of clinical health professionals nowadays is to improve the management of pain in their patients. Pain is a multifactorial phenomenon and knowledge of the complexity of pain pathways is growing, as demonstrated by current research. The concept of multimodal analgesia involves the use of different classes of analgesics (table III) and different sites of analgesic administration to provide superior dynamic pain relief with reduced analgesic-related adverse effects.^[164] A multimodal approach is associated with an increase in patient satisfaction and a reduction in adverse effects compared with those resulting from single analgesic techniques in pain management.^[165-167] The use of nonpharmacological options, such as acupuncture, relaxation and transcutaneous nerve stimulation, as adjuvants to conventional analgesia can also be considered, and incorporated to achieve an effective and successful pain management regimen in some patients.^[167]

12. Conclusions

Many treatment modalities are being used to reduce and alleviate pain; however, many clinical questions are still unanswered. This is attributed to the complexity of the process involved. Indeed, the research and treatments concerning the field of pain management are in the early stages of development, with many unmet goals. In the coming years, several advances are expected in the basic and clinical sci-

Table III. Clinical pharmacology of drugs commonly used in the treatment of pain

Drug class ^a	Indications	Route of administration	Adverse effects	Contraindications
Opioids	Treatment of pain such as acute, postoperative, neuropathic, inflammatory, cancer	Oral, intravenous, transdermal (patch), sublingual spray, intranasal spray, oral transmucosal, pulmonary, microspheres	Respiratory depression, sedation, nausea and vomiting, constipation, cognitive dysfunction, pruritus, tolerance/dependence, euphoria	Screen patients for alcohol/substance abuse; coadminister pre-emptive stool softeners and antiemetics
NSAIDs (traditional)	Prescribed as analgesics and anti-inflammatory agents	Oral, intravenous, intramuscular, topical	Gastrointestinal disturbances, renal, skin reactions	Patients with gastrointestinal and renal complications
Coxibs ^b	Relief of osteoarthritis, rheumatoid arthritis, acute and postoperative pain	Oral, intravenous	Cardiac (myocardial infarction and stroke), gastrointestinal problems with long-term use, renal (acute renal failure)	Patients with cardiovascular and cerebrovascular disease; care in patients with hypertension, hyperlipidaemia, diabetes mellitus, arterial disease or smoking
Antidepressants	Neuropathic pain	Oral	Sedation, constipation, dry mouth, orthostatic hypotension and weight gain using tricyclic antidepressants; ataxia, nausea and anorexia using newer antidepressants	Patients with glaucoma and/or taking monoamine oxidase inhibitors; duloxetine has been approved by US FDA for use in diabetic neuropathy.
Antiepileptic drugs	Painful diabetic neuropathy, post-herpetic neuralgia and trigeminal neuralgia	Oral	Sedation, ataxia, oedema, weight gain, diplopia	Patients with renal dysfunction need a dose adjustment
Cannabinoids	Chronic pain	Oral, sublingual spray, inhalation	Euphoria, memory impairment, tachycardia, tolerance	Patients with hypertension and ischaemic heart disease
Local anaesthetics	Blocking evoked pain	Local/regional, transdermal (patch), intravenous, neuroaxial (spinal, epidural)	Skin erythema, rash, convulsions, coma, cardiorespiratory depression with increasing doses	Those associated with loco-regional anaesthesia: non-consenting patient, local infection, coagulation disorders, inadequate monitoring

a See table I for lists of drugs within each class that are commonly used.

b Selective cyclo-oxygenase type 2 inhibitors.

ences of pain, which will provide improved new therapies for patients. Since treatment paradigms are shifting from single-drug trials to multiple-drug therapies, research in multiple-drug therapy is needed in order to better alleviate pain in patients. Increased knowledge of the complexity of the pain pathways is responsible for this necessity for new strategies involving combined medication. Therefore, medical education will be necessary to explain and better understand the importance of multiple drug therapy in the near future.

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

1. Hudcova J, McNicol E, Quah C, et al. Patient controlled opioid analgesia versus conventional opioid analgesia for post-operative pain. *Cochrane Database Syst Rev* 2006; (4): CD003348
2. Zech DF, Lehmann KA. Transdermal fentanyl in combination with initial intravenous dose titration by patient-controlled analgesia. *Anticancer Drugs* 1995; 6: 44-9

3. Grond S, Zech D, Lehmann KA, et al. Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. *Pain* 1997; 69: 191-8
4. Lehr VT, Renaud EA. High transdermal fentanyl requirements in a patient with chronic cancer pain. *Ann Pharmacother* 1993; 27: 575-8
5. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. *Palliat Med* 2006; 20 Suppl. 1: s25-30
6. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long-term control of chronic pain in cancer patients. *Front Biosci* 2007; 12: 1291-9
7. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. *Clin Ther* 2005; 27: 225-37
8. Louis F. Transdermal buprenorphine in pain management: experiences from clinical practice. Five case studies. *Int J Clin Pract* 2006; 60: 1330-4
9. Gourlay GK, Kowalski SR, Plummer JL, et al. The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. *Pain* 1989; 37: 193-202
10. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. *Anesthesiology* 1989; 70: 928-34
11. Chelly JE, Grass J, Houseman TW, et al. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. *Anesth Analg* 2004; 98: 427-33
12. Viscusi ER, Reynolds L, Chung F, et al. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. *JAMA* 2004; 291: 1333-41
13. Chelly JE. An iontophoretic, fentanyl HCl patient-controlled transdermal system for acute postoperative pain management. *Expert Opin Pharmacother* 2005; 6: 1205-14
14. Koo PJ. Postoperative pain management with a patient-controlled transdermal delivery system for fentanyl. *Am J Health Syst Pharm* 2005; 62: 1171-6
15. Vercauteren M, Boeckx E, Hanegreets G, et al. Intranasal sufentanil for pre-operative sedation. *Anaesthesia* 1988; 43: 270-3
16. Striebel HW, Koenigs D, Krämer J. Postoperative pain management by intranasal demand-adapted fentanyl titration. *Anesthesiology* 1992; 77: 281-5
17. Schwagmeier R, Boerger N, Meissner W, et al. Pharmacokinetics of intranasal alfentanil. *J Clin Anesth* 1995; 7: 109-13
18. Striebel HW, Bonillo B, Schwagmeier R, et al. Self-administered intranasal meperidine for postoperative pain management. *Can J Anaesth* 1995; 42: 287-91
19. Mitchell TB, Lintzeris N, Bond A, et al. Feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment. *Eur Addict Res* 2006; 12: 91-5
20. Wermeling DP, Grant GM, Lee A, et al. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 2005; 27: 430-40
21. Striebel HW, Olmann T, Spies C, et al. Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. *J Clin Anesth* 1996; 8: 4-8
22. Al-Ghananeem AM, Malkawi AH, Crooks PA. Effect of pH on sublingual absorption of oxycodone hydrochloride. *AAPS PharmSciTech* 2006; 7: E1-5
23. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. *Pain* 2004; 112: 299-306
24. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. *Clin Rehabil* 2003; 17: 21-9
25. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. *Anaesthesia* 2004; 59: 440-52
26. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology* 2005; 65: 812-9
27. Ware M, Beaulieu P. Cannabinoids for the treatment of pain: an update on recent clinical trials. *Pain Res Manag* 2005; 10: 27-30A
28. Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. *Trends Pharmacol Sci* 2006; 27: 134-40
29. Mercadante S, Fulfaro F. Alternatives to oral opioids for cancer pain. *Oncology* 1999; 13: 215-20
30. Mystakidou K, Katsouda E, Parpa E, et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. *Am J Hosp Palliat Care* 2005; 22: 228-32
31. Mystakidou K, Katsouda E, Parpa E, et al. Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. *Drug Deliv* 2006; 13: 269-76
32. Masood AR, Thomas SH. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. *Br J Clin Pharmacol* 1996; 41: 250-2
33. Gonda I, Schuster JA, Rubsamen RM, et al. Inhalation delivery systems with compliance and disease management capabilities. *J Control Release* 1998; 53: 269-74
34. Gonda I, Fiore M, Johansson ET, et al. Bolus delivery of morphine solutions with the AERx pain management system (PMS) [abstract]. *J Aerosol Med* 1999; 12: 114
35. Boyle F, Mather LE, Lam J, et al. Inhaled fentanyl via the AERx™ system for the treatment of breakthrough cancer pain [poster no. 630]. 19th Annual Scientific Meeting of the American Pain Society; 2000 Nov 2-5; Atlanta (GA)
36. Slatkin N, Rauck R, Koczwara B, et al. Analgesic efficacy of inhaled morphine delivered with the AERx™ mPMS for breakthrough cancer pain. *J Pain* 2002; 3: 43
37. Thippawong J, Babul N, Morishige R, et al. Analgesic efficacy of inhaled morphine in patients after bunionectionomy surgery. *Anesthesiology* 2003; 99: 693-700
38. Hung OR, Whynot SC, Varvel JR, et al. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. *Anesthesiology* 1995; 83: 277-84
39. Tuncay M, Calis S, Kas HS, et al. In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. *J Microencapsul* 2000; 17: 145-55
40. Yen SY, Sung KC, Wang JJ, et al. Controlled release of nalbuphine propionate from biodegradable microspheres: in vitro and in vivo studies. *Int J Pharm* 2001; 220: 91-9
41. Thakkar H, Sharma RK, Mishra AK, et al. Efficacy of chitosan microspheres for controlled intra-articular delivery of celecoxib in inflamed joints. *J Pharm Pharmacol* 2004; 56: 1091-9
42. Sciuilli MG, Capone ML, Tacconelli S, et al. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. *Pharmacol Rep* 2005; 57: 66-85
43. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. *J Clin Invest* 2001; 108: 7-13

44. Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. *Expert Opin Drug Metab Toxicol* 2005; 1: 269-82
45. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet* 2006; 368: 1771-81
46. Fenton C, Keating GM, Wagstaff AJ. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. *Drugs* 2004; 64: 1231-61
47. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). *Drugs* 2001; 61: 1133-41
48. Langford RM. Are COX-2 selective inhibitors safe for post-operative pain treatment? Yes and no. *Acute Pain* 2006; 8: 95-7
49. Nussmeier NA, Whelton AA, Brown MT, et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. *Anesthesiology* 2006; 104: 518-26
50. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. *Lancet* 2004; 364: 675-84
51. Wittenberg RH, Schell E, Krehan G, et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]. *Arthritis Res Ther* 2006; 8: 1-9
52. Doggrell SA. The safety of lumiracoxib when used in the treatment of arthritis. *Expert Opin Pharmacother* 2005; 6: 347-50
53. Langford RM. Pain management: what have we learned? *Clin Rheumatol* 2006; 25 Suppl. 1: S2-8
54. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 2000; 343: 1520-8
55. Food and Drug Administration. FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). Rockville (MD): FDA; 2005
56. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg* 2003; 125: 1481-92
57. European Medicines Agency. EMEA press release: European medicines agency concludes action on COX-2 inhibitors [online]. Available from URL: <http://www.emea.europa.eu/pdfs/human/press/pr/20776605en.pdf> [Accessed 2007 Aug 27]
58. Marret E, Kurdi O, Zufferey P, et al. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects. *Anesthesiology* 2005; 102: 1249-60
59. Power I. Recent advances in postoperative pain therapy. *Br J Anaesth* 2005; 95: 43-51
60. White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. *Anesth Analg* 2005; 101 Suppl. 5: S5-22
61. Topol EJ. Arthritis medicines and cardiovascular events: 'house of coxibs'. *JAMA* 2005; 293: 366-8
62. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med* 2005; 352: 1081-91
63. Harris RC. COX-2 and the kidney. *J Cardiovasc Pharmacol* 2006; 47 Suppl. 1: S37-42
64. Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. *CMAJ* 2004; 171: 333-8
65. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. *BMC Musculoskelet Disord* 2005; 6: 1-9
66. Banning M. The use of topical diclofenac for pain in osteoarthritis of the knee: a review. *Br J Community Nurs* 2006; 11: 487-92
67. Holmer Pettersson P, Owall A, Jakobsson J. Early bioavailability of paracetamol after oral or intravenous administration. *Acta Anaesthesiol Scand* 2004; 48: 867-70
68. Holmer Pettersson P, Jakobsson J, Owall A. Plasma concentrations following repeated rectal or intravenous administration of paracetamol after heart surgery. *Acta Anaesthesiol Scand* 2006; 50: 673-7
69. McNicol E, Strassels SA, Goudas L, et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. *Cochrane Database Syst Rev* 2005; (2): CD005180
70. Kampe S, Warm M, Landwehr S, et al. Clinical equivalence of IV paracetamol compared to IV dipyrone for postoperative analgesia after surgery for breast cancer. *Curr Med Res Opin* 2006; 22: 1949-54
71. Romsing J, Moinicke S, Dahl JB. Rectal and parenteral paracetamol, and paracetamol in combination with NSAIDs, for postoperative analgesia. *Br J Anaesth* 2002; 88: 215-26
72. Hyllested M, Jones S, Pedersen JL, et al. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. *Br J Anaesth* 2002; 88: 199-214
73. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. *Br J Anaesth* 2005; 94: 505-13
74. Hahn TW, Mogensen T, Lund C, et al. Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in post-operative pain. *Acta Anaesthesiol Scand* 2003; 47: 138-45
75. Alhashemi JA, Alotaibi QA, Mashaat MS, et al. Intravenous acetaminophen vs oral ibuprofen in combination with morphine PCA after Cesarean delivery. *Can J Anaesth* 2006; 53: 1200-6
76. Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. *Anesthesiology* 2005; 103: 1296-304
77. Bonnefont J, Courade JP, Alloui A, et al. Antinociceptive mechanism of action of paracetamol. *Drugs* 2003; 63: 1-4
78. Pickering G, Lorient MA, Libert F, et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. *Clin Pharmacol Ther* 2006; 79: 371-8
79. Mimos O, Incagnoli P, Josse C, et al. Analgesic efficacy and safety of nefopam vs propacetamol following hepatic resection. *Anaesthesia* 2001; 56: 520-5
80. Du Manoir B, Aubrun F, Langlois M, et al. Randomized prospective study of the analgesic effect of nefopam after orthopaedic surgery. *Br J Anaesth* 2003; 91: 836-41
81. Kapfer B, Alfonsi P, Guignard B, et al. Nefopam and ketamine comparably enhance postoperative analgesia. *Anesth Analg* 2005; 100: 169-74
82. Tramoni G, Viale JP, Cazals C, et al. Morphine-sparing effect of nefopam by continuous intravenous injection after abdominal surgery by laparotomy. *Eur J Anaesthesiol* 2003; 20: 990-2
83. Delage N, Maaliki H, Beloeil H, et al. Median effective dose (ED50) of nefopam and ketoprofen in postoperative patients: a study of interaction using sequential analysis and isobolographic analysis. *Anesthesiology* 2005; 102: 1211-6

84. Gasser JC, Bellville JW. Respiratory effects of nefopam. *Clin Pharmacol Ther* 1975; 18: 175-9
85. Heel RC, Brogden RN, Pakes GE, et al. Nefopam: a review of its pharmacological properties and therapeutic efficacy. *Drugs* 1980; 19: 249-67
86. Dordoni PL, Della Ventura M, Stefanelli A, et al. Effect of ketorolac, ketoprofen and nefopam on platelet function. *Anaesthesia* 1994; 49: 1046-9
87. Piercey MF, Schroeder LA. Spinal and supraspinal sites for morphine and nefopam analgesia in the mouse. *Eur J Pharmacol* 1981; 74: 135-40
88. Guirimand F, Dupont X, Bouhassira D, et al. Nefopam strongly depresses the nociceptive flexion (R(III)) reflex in humans. *Pain* 1999; 80: 399-404
89. Rosland JH, Hole K. The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations. *J Pharm Pharmacol* 1990; 42: 437-8
90. Fuller RW, Snoddy HD. Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice. *Neuropharmacology* 1993; 32: 995-9
91. Girard P, Coppé MC, Verniers D, et al. Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception. *Pharmacol Res* 2006; 54: 195-202
92. Hunskaar S, Fasmer OB, Broch OJ, et al. Involvement of central serotonergic pathways in nefopam-induced antinociception. *Eur J Pharmacol* 1987; 138: 77-82
93. Fernandez-Sanchez MT, Diaz-Trelles R, Groppetti A, et al. Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent veratridine-induced neurotoxicity. *Amino Acids* 2002; 23: 31-6
94. Verleye M, André N, Heulard I, et al. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. *Brain Res* 2004; 1013: 249-55
95. Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. *Cochrane Database Syst Rev* 2006; (3): CD003726
96. Shamim F, Hoda MQ, Samad K, et al. Comparison between tramadol and pethidine in patient controlled intravenous analgesia. *J Pak Med Assoc* 2006; 56: 433-6
97. Ozalevli M, Unlugenc H, Tuncer U, et al. Comparison of morphine and tramadol by patient-controlled analgesia for postoperative analgesia after tonsillectomy in children. *Paediatr Anaesth* 2005; 15: 979-84
98. Perrot S, Krause D, Crozes P, et al. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in patients with subacute low back pain: a multicenter, randomized, double-blind, parallel-group, 10-day treatment study. *Clin Ther* 2006; 28: 1592-606
99. Hewitt DJ, Todd KH, Xiang J, et al. Tramadol/acetaminophen or hydrocodone/acetaminophen for the treatment of ankle sprain: a randomized, placebo-controlled trial. *Ann Emerg Med* 2007; 49 (4): 468-80
100. Morley JS, Bridson J, Nash TP, et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. *Palliat Med* 2003; 17: 576-87
101. Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. *Pain Res Manag* 2005; 10: 133-44
102. Moulin DE, Palma D, Watling C, et al. Methadone in the management of intractable neuropathic noncancer pain. *Can J Neurol Sci* 2005; 32: 340-3
103. Davis M, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. *Support Care Cancer* 2001; 9: 73-83
104. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. *J Clin Oncol* 2001; 19: 2898-904
105. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. *J Palliat Med* 2002; 5: 127-38
106. Moulin DE. Methadone: an old analgesic with new tricks [letter]. *Pain Res Manag* 2005; 10: 131
107. Mesolella M, Lamarca S, Galli V, et al. Use of remifentanyl for sedo-analgesia in stapedotomy: personal experience. *Acta Otorhinolaryngol Ital* 2004; 24: 315-20
108. Kucukemre F, Kunt N, Kaygusuz K, et al. Remifentanyl compared with morphine for postoperative patient-controlled analgesia after major abdominal surgery: a randomized controlled trial. *Eur J Anaesthesiol* 2005; 22: 378-85
109. Steinlechner B, Koinig H, Grubhofer G, et al. Postoperative analgesia with remifentanyl in patients undergoing cardiac surgery. *Anesth Analg* 2005; 100: 1230-5
110. Blancas Gomez-Casero R, Martin Delgado C, Nevado Losada E, et al. Sedoanalgesia with remifentanyl in definitive pacemaker implant. *Med Intensiva* 2006; 30: 370-3
111. Thurlow JA, Waterhouse P. Patient-controlled analgesia in labour using remifentanyl in two parturients with platelet abnormalities. *Br J Anaesth* 2000; 84: 411-3
112. Novoa L, Navarro Egea M, Vieito Amor M, et al. Obstetric analgesia and anesthesia with remifentanyl in a patient with von Willebrand disease. *Rev Esp Anesthesiol Reanim* 2003; 50: 242-4
113. Blair JM, Dobson GT, Hill DA, et al. Patient controlled analgesia for labour: a comparison of remifentanyl with pethidine. *Anaesthesia* 2005; 60: 22-7
114. Tofil NM, Benner KW, Faro SJ, et al. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. *Pediatr Crit Care Med* 2006; 7: 252-4
115. Yuan CS. Clinical status of methyl-naltrexone, a new agent to prevent and manage opioid-induced side effects. *J Support Oncol* 2004; 2: 111-7
116. Visser E, Schug SA. The role of ketamine in pain management. *Biomed Pharmacother* 2006; 60: 341-8
117. Webster LR, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. *Am J Ther* 2006; 13: 300-5
118. Lynch ME, Clark AJ, Sawynok J, et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. *J Pain* 2005; 6: 644-9
119. Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. *Support Care Cancer* 2005; 13: 188-93
120. Chung WJ, Pharo GH. Successful use of ketamine infusion in the treatment of intractable cancer pain in an outpatient. *J Pain Symptom Manage* 2007; 33: 2-5
121. Wang X, Xie H, Wang G. Improved postoperative analgesia with coadministration of preoperative epidural ketamine and midazolam. *J Clin Anesth* 2006; 18: 563-9
122. McCartney CJ, Sinha A, Katz J. A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia. *Anesth Analg* 2004; 98: 1385-400
123. Elia N, Tramèr MR. Ketamine and postoperative pain: a quantitative systematic review of randomised trials. *Pain* 2005; 113: 61-70
124. Mattia C, Paoletti F, Coluzzi F, et al. New antidepressants in the treatment of neuropathic pain: a review. *Minerva Anesthesiol* 2002; 68: 105-14
125. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev* 2005; (3): CD005454

126. Vadalouca A, Siafaka I, Argyra E, et al. Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. *Ann N Y Acad Sci* 2006; 1088: 164-86
127. Dick IE, Brochu RM, Purohit Y, et al. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. *J Pain* 2007; 8 (4): 315-24
128. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med* 1992; 326: 1250-6
129. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. *Pain* 1996; 64: 293-302
130. Reisner L. Antidepressants for chronic neuropathic pain. *Curr Pain Headache Rep* 2003; 7: 24-33
131. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. *Ann Pharmacother* 2001; 35: 557-9
132. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. *Neurology* 2003; 60: 1284-9
133. Davis MP. What is new in neuropathic pain? *Support Care Cancer* 2007; 15 (4): 363-72
134. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. *Pain Med* 2005; 6: 346-56
135. Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. *Pain Med* 2006; 7: 373-85
136. Simmons Z, Feldman EL. Update on diabetic neuropathy. *Curr Opin Neurol* 2002; 15: 595-603
137. Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. *Basic Clin Pharmacol Toxicol* 2005; 96: 399-409
138. Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. *Eur J Pain* 2002; 6 Suppl. A: 61-8
139. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. *CMAJ* 2006; 175: 265-75
140. Tenser RB, Dworkin RH. Herpes zoster and the prevention of postherpetic neuralgia: beyond antiviral therapy. *Neurology* 2005; 65: 349-50
141. Dickenson AH, Ghandehari J. Anti-convulsants and anti-depressants. *Handb Exp Pharmacol* 2007; 177: 145-77
142. Gilron I, Flatters SJ. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. *Pain Res Manag* 2006; 11: 16-29A
143. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. *Drugs* 2000; 60: 1029-52
144. Gilron I. The role of anticonvulsant drugs in postoperative pain management: a bench-to-bedside perspective (review article). *Can J Anesth* 2006; 53: 552-71
145. Seib RK, Paul JE. Preoperative gabapentin for postoperative analgesia: a meta-analysis. *Can J Anesth* 2006; 53: 461-9
146. Boezaart AP. Perineural infusion of local anesthetics. *Anesthesiology* 2006; 104: 872-80
147. Ilfeld BM, Enck FK. Continuous peripheral nerve blocks at home: a review. *Anesth Analg* 2005; 100: 1822-33
148. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. *Pain* 2005; 118: 289-305
149. Kang L, Jun HW. Formulation and efficacy studies of new topical anesthetic creams. *Drug Dev Ind Pharm* 2003; 29: 505-12
150. Batra YK, Mahajan R, Bangalia SK, et al. Bupivacaine/ketamine is superior to intra-articular ketamine analgesia following arthroscopic knee surgery. *Can J Anesth* 2005; 52: 832-6
151. Harvey GP, Chelly JE, AlSamsam T, et al. Patient-controlled ropivacaine analgesia after arthroscopic subacromial decompression. *Arthroscopy* 2004; 20: 451-5
152. Karamanlioglu B, Turan A, Memis D, et al. Infiltration with ropivacaine plus lornoxicam reduces postoperative pain and opioid consumption. *Can J Anesth* 2005; 52: 1047-53
153. Ashton CH, editor. Therapeutic uses of cannabis. London: British Medical Association, 1997
154. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA* 2003; 290: 1757-62
155. Ware MA, Doyle CR, Woods R, et al. Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain* 2003; 102 (1-2): 211-6
156. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* 2003; 362 (9395): 1517-26
157. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 2004; 329 (7460): 253
158. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. *Pain Med* 2006; 7: 25-9
159. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. *J Neurol* 2006; 253: 1337-41
160. Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. *J Clin Pharmacol* 1981; 21: 320-326S
161. Holdcroft A, Maze M, Doré C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. *Anesthesiology* 2006; 104: 1040-6
162. Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. *Pain* 2003; 106: 169-72
163. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. *Can J Anesth* 2006; 53: 769-75
164. Joshi GP. Multimodal analgesia techniques and postoperative rehabilitation. *Anesthesiol Clin North America* 2005; 1: 185-202
165. Brodnier G, Van Aken H, Hertle L, et al. Multimodal perioperative management: combining thoracic epidural analgesia, forced mobilization, and oral nutrition reduces hormonal and metabolic stress and improves convalescence after major urologic surgery. *Anesth Analg* 2001; 92: 1594-600
166. Mugabure Bujedo B, Bizueta IT, Santos SG, et al. Multimodal approaches to postoperative pain management and convalescence. *Rev Esp Anestesiol Reanim* 2007; 54: 29-40
167. Pyati S, Gan TJ. Perioperative pain management. *CNS Drugs* 2007; 21: 185-211

Correspondence: Dr *Pierre Beaulieu*, Department of Anesthesiology, CHUM – Hôtel-Dieu, 3840 rue St-Urbain, Montréal, H2W 1T8, QC, Canada.
E-mail: pierre.beaulieu@umontreal.ca